NEW YORK, Oct. 20, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the United States Patent and Trademark Office has issued a patent covering therapeutic applications of its lead compound, PT-112, as an immuno-modulatory agent, both as a monotherapy and in combination with other immunotherapy approaches.
PT-112 has been validated as a highly potent immunogenic cell death (ICD) inducer in peer-reviewed publications in the journals OncoImmunology and Cancers, and in presentations at major research forums including the AACR and ENA annual conferences. PT-112's ICD property involves the release of so-called damage associated molecular patterns (DAMPs) that bind with and activate dendritic cells, leading to trafficking of activated T cells to the tumor microenvironment. PT-112 is currently in three Phase 2 clinical trials: for metastatic castration-resistant prostate cancer; thymic epithelial tumors; and in combination with PD-L1 checkpoint inhibition for non-small cell lung cancer.
"As an immunogenic small molecule, PT-112 has the potential to play an important role in overcoming areas of immunotherapy drug resistance, which continues to limit effective treatment options for patients," said Promontory President and Chief Executive Officer Robert Fallon. "This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."
The patent, titled "Phosphaplatin Compounds as Immuno-Modulatory Agents and Therapeutic Uses Thereof," was issued on Sept. 13, 2022 as U.S. Patent No. 11,439,619 B2.
For more information about Promontory Therapeutics' clinical pipeline visit www.PromontoryTx.com.
PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a highly potent inducer of this immunological form of cancer cell death. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The ?rst in-human study of PT-112 demonstrated an attractive safety pro?le and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The combination Phase 1b dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress. The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH is the third completed Phase 1 study of PT-112. Monotherapy Phase 2 development is ongoing in mCRPC, and now includes the Phase 2 proof of concept study in thymic epithelial tumors under the company's formal collaboration with the NCI. The PD-L1 combination Phase 2a study in a dose confirmation cohort of non-small cell lung cancer (NSCLC) patients will be presented at the 2022 ESMO Immuno-Oncology conference.
Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy. The company's lead candidate, PT-112, is the first small molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes cancer cell organelle stresses leading to immunogenic cell death (ICD), and the downstream adaptive anti-cancer immune response. Clinical data generated across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability pro?le, and three Phase 2 studies of PT-112 are underway. The company's research and development work has been conducted in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with P?zer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active Phase 2 trial underway under formal collaboration with the National Cancer Institute (NCI), utilizing PT-112 in thymic epithelial tumors, where PT-112 has received Orphan Drug designation.
To learn more about Promontory Therapeutics, visit the company's website here.
Taylor B. Young
Senior Director, Strategic Development
Tel: +1 646 380 2441
Email: [email protected]
Tel: +1 646 277 1282
Email: [email protected]
Tel: +1 203 682 8288
Email: [email protected]
SOURCE Promontory Therapeutics Inc.
These press releases may also interest you